category

Earnings Report

What's On Our Radar: November 10, 2016

Here’s what’s On Our Radar for today: President Obama and President-elect Donald Trump are going to have some quality face time today at the White House.

What's On Our Radar: November 10, 2016

Here’s what’s On Our Radar for today: President Obama and President-elect Donald Trump are going to have some quality face time today at the White House.

Macy's 3Q Earnings Miss Expectations

Macy's reported a 4.2 percent fall in third-quarter sales, and said it had formed a partnership with asset manager Brookfield Asset Management to enhance the value of its real estate.

Macy's 3Q Earnings Miss Expectations

Macy's reported a 4.2 percent fall in third-quarter sales, and said it had formed a partnership with asset manager Brookfield Asset Management to enhance the value of its real estate.

Kohl's Profit Beats Estimates

Department store operator Kohl's reported a better-than-expected 21.7 percent jump in quarterly profit on Thursday, helped mainly by cost-cutting.

Kohl's Profit Beats Estimates

Department store operator Kohl's reported a better-than-expected 21.7 percent jump in quarterly profit on Thursday, helped mainly by cost-cutting.

Drug firm AstraZeneca says 3Q earnings fall 12 percent.

Anglo-Swedish drugmaker AstraZeneca says third-quarter earnings fell 12 percent as its blockbuster cholesterol drug Crestor faced its first full quarter of competition in the United States from generic alternatives.

Drug firm AstraZeneca says 3Q earnings fall 12 percent.

Anglo-Swedish drugmaker AstraZeneca says third-quarter earnings fell 12 percent as its blockbuster cholesterol drug Crestor faced its first full quarter of competition in the United States from generic alternatives.

Mylan sees 3Q loss due to settlement for EpiPen overcharges

Drugmaker Mylan Inc. swung to a third-quarter loss, mainly due to a big settlement for overcharging the federal government for its controversial EpiPen, the emergency allergy injector whose price Mylan has repeatedly jacked up.

Mylan sees 3Q loss due to settlement for EpiPen overcharges

Drugmaker Mylan Inc. swung to a third-quarter loss, mainly due to a big settlement for overcharging the federal government for its controversial EpiPen, the emergency allergy injector whose price Mylan has repeatedly jacked up.